Johnson & Johnson: A Strong Dividend Investment Amid Market Volatility
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy JNJ?
Source: Fool
- Dividend Growth Record: Johnson & Johnson has increased its dividends for 63 consecutive years, establishing itself as a leader among Dividend Kings, which showcases its ability to provide stable returns during economic turmoil, thus attracting safety-seeking investors.
- Strong Sales Projections: The company is projected to achieve $100 billion in sales this year, marking it as only the second biopharma company to reach this milestone, which will enhance its market position and boost investor confidence.
- Diversified Product Portfolio: Johnson & Johnson's pharmaceutical division includes numerous drugs with annual sales exceeding $1 billion, enabling it to effectively navigate challenges posed by patent expirations, ensuring continued growth in a competitive market.
- Financial Health: With an AAA rating from S&P Global, Johnson & Johnson demonstrates robust financial health, allowing it to continue investing in R&D and increasing dividends amidst economic uncertainty, thereby enhancing its long-term investment appeal.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 242.490
Low
190.00
Averages
218.50
High
240.00
Current: 242.490
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson's Strong Operations Support Dividend Growth
- Dividend Growth History: Johnson & Johnson has increased its dividends for 63 consecutive years, establishing itself as a Dividend King, which enhances investor confidence in its ability to maintain stable payouts amid economic volatility.
- Sales Growth Projection: The company is projected to reach $100 billion in sales this year, marking it as only the second biopharma company to achieve this milestone, despite challenges from government price negotiations, showcasing its strong market position and product demand.
- Diversified Product Line: Johnson & Johnson's pharmaceutical business spans several major therapeutic areas with multiple drugs generating over $1 billion in annual sales, effectively mitigating risks associated with patent expirations and ensuring long-term profitability.
- Financial Health: With an AAA rating from S&P Global, Johnson & Johnson demonstrates exceptional financial health, positioning itself to perform strongly amid economic uncertainties, further solidifying its status as a preferred choice for investors.
See More
Johnson & Johnson: A Strong Dividend Investment Amid Market Volatility
- Dividend Growth Record: Johnson & Johnson has increased its dividends for 63 consecutive years, establishing itself as a leader among Dividend Kings, which showcases its ability to provide stable returns during economic turmoil, thus attracting safety-seeking investors.
- Strong Sales Projections: The company is projected to achieve $100 billion in sales this year, marking it as only the second biopharma company to reach this milestone, which will enhance its market position and boost investor confidence.
- Diversified Product Portfolio: Johnson & Johnson's pharmaceutical division includes numerous drugs with annual sales exceeding $1 billion, enabling it to effectively navigate challenges posed by patent expirations, ensuring continued growth in a competitive market.
- Financial Health: With an AAA rating from S&P Global, Johnson & Johnson demonstrates robust financial health, allowing it to continue investing in R&D and increasing dividends amidst economic uncertainty, thereby enhancing its long-term investment appeal.
See More
Royalty Pharma Partners with Johnson & Johnson in $500M R&D Deal
- Collaborative R&D Agreement: Royalty Pharma has entered into a $500 million R&D funding agreement with Johnson & Johnson, aimed at supporting the development of a new autoimmune treatment between 2026 and 2027, highlighting the potential for deep collaboration in the biopharmaceutical sector.
- New Therapy Development: The partnership will focus on JNJ-4804, a novel co-antibody therapy that blocks both IL-23 and tumor necrosis factor (TNF) pathways, delivering synergistic effects on the pathogenesis of chronic immune-mediated diseases, potentially offering more effective treatment options for patients.
- Market Impact: This collaboration not only accelerates the clinical development of the new therapy but also enhances the competitive positioning of both Royalty Pharma and Johnson & Johnson in the autoimmune disease treatment market, further solidifying their leadership in the biopharmaceutical industry.
- Strategic Significance: Through this partnership, Royalty Pharma demonstrates its commitment to innovative drug development while adding new treatment options to Johnson & Johnson's product line, indicating ongoing investment and growth potential in the biopharmaceutical field.
See More
Royalty Pharma and Johnson & Johnson Sign $500 Million Co-Funding Agreement
- Co-Funding Agreement: Royalty Pharma's $500 million co-funding agreement with Johnson & Johnson aims to advance the development of JNJ-4804 in 2026 and 2027, highlighting the company's strategic investment intentions in the biopharmaceutical sector.
- Innovative Drug Development: JNJ-4804 is a co-antibody therapy designed to block complementary interleukin-23 and tumor necrosis factor pathways, which, if successful, will provide new treatment options for autoimmune disease patients and further solidify Royalty Pharma's position in biopharmaceutical innovation.
- Portfolio Expansion: Royalty Pharma's current portfolio includes royalties on over 35 commercial products and 19 development-stage candidates, and this collaboration is expected to enhance its influence and competitiveness in the biopharmaceutical industry.
- Positive Market Reaction: In pre-market trading on Nasdaq, Royalty Pharma shares rose 1.4% to $47.00, reflecting market optimism regarding the co-funding agreement and its potential financial benefits.
See More
Royalty Pharma Enters Agreement to Propel Development of JNJ-4804 for Autoimmune Disorders
Agreement Overview: Royalty Pharma has entered into an agreement to advance the development of JNJ-4804, a treatment for autoimmune diseases.
Focus on Autoimmune Diseases: The collaboration aims to enhance the research and development efforts for JNJ-4804, targeting various autoimmune conditions.
See More
Royalty Pharma Reveals $500 Million R&D Co-Funding Partnership with Johnson & Johnson for 2026-2027
Funding Announcement: Royalty Pharma has announced a $500 million R&D co-funding agreement with Johnson & Johnson for the years 2026-2027.
Collaboration Details: The agreement aims to support the development of innovative therapies and enhance research capabilities between the two companies.
See More
Johnson & Johnson's Strong Operations Support Dividend Growth
- Dividend Growth History: Johnson & Johnson has increased its dividends for 63 consecutive years, establishing itself as a Dividend King, which enhances investor confidence in its ability to maintain stable payouts amid economic volatility.
- Sales Growth Projection: The company is projected to reach $100 billion in sales this year, marking it as only the second biopharma company to achieve this milestone, despite challenges from government price negotiations, showcasing its strong market position and product demand.
- Diversified Product Line: Johnson & Johnson's pharmaceutical business spans several major therapeutic areas with multiple drugs generating over $1 billion in annual sales, effectively mitigating risks associated with patent expirations and ensuring long-term profitability.
- Financial Health: With an AAA rating from S&P Global, Johnson & Johnson demonstrates exceptional financial health, positioning itself to perform strongly amid economic uncertainties, further solidifying its status as a preferred choice for investors.
See More
Johnson & Johnson: A Strong Dividend Investment Amid Market Volatility
- Dividend Growth Record: Johnson & Johnson has increased its dividends for 63 consecutive years, establishing itself as a leader among Dividend Kings, which showcases its ability to provide stable returns during economic turmoil, thus attracting safety-seeking investors.
- Strong Sales Projections: The company is projected to achieve $100 billion in sales this year, marking it as only the second biopharma company to reach this milestone, which will enhance its market position and boost investor confidence.
- Diversified Product Portfolio: Johnson & Johnson's pharmaceutical division includes numerous drugs with annual sales exceeding $1 billion, enabling it to effectively navigate challenges posed by patent expirations, ensuring continued growth in a competitive market.
- Financial Health: With an AAA rating from S&P Global, Johnson & Johnson demonstrates robust financial health, allowing it to continue investing in R&D and increasing dividends amidst economic uncertainty, thereby enhancing its long-term investment appeal.
See More
Royalty Pharma Partners with Johnson & Johnson in $500M R&D Deal
- Collaborative R&D Agreement: Royalty Pharma has entered into a $500 million R&D funding agreement with Johnson & Johnson, aimed at supporting the development of a new autoimmune treatment between 2026 and 2027, highlighting the potential for deep collaboration in the biopharmaceutical sector.
- New Therapy Development: The partnership will focus on JNJ-4804, a novel co-antibody therapy that blocks both IL-23 and tumor necrosis factor (TNF) pathways, delivering synergistic effects on the pathogenesis of chronic immune-mediated diseases, potentially offering more effective treatment options for patients.
- Market Impact: This collaboration not only accelerates the clinical development of the new therapy but also enhances the competitive positioning of both Royalty Pharma and Johnson & Johnson in the autoimmune disease treatment market, further solidifying their leadership in the biopharmaceutical industry.
- Strategic Significance: Through this partnership, Royalty Pharma demonstrates its commitment to innovative drug development while adding new treatment options to Johnson & Johnson's product line, indicating ongoing investment and growth potential in the biopharmaceutical field.
See More
Royalty Pharma and Johnson & Johnson Sign $500 Million Co-Funding Agreement
- Co-Funding Agreement: Royalty Pharma's $500 million co-funding agreement with Johnson & Johnson aims to advance the development of JNJ-4804 in 2026 and 2027, highlighting the company's strategic investment intentions in the biopharmaceutical sector.
- Innovative Drug Development: JNJ-4804 is a co-antibody therapy designed to block complementary interleukin-23 and tumor necrosis factor pathways, which, if successful, will provide new treatment options for autoimmune disease patients and further solidify Royalty Pharma's position in biopharmaceutical innovation.
- Portfolio Expansion: Royalty Pharma's current portfolio includes royalties on over 35 commercial products and 19 development-stage candidates, and this collaboration is expected to enhance its influence and competitiveness in the biopharmaceutical industry.
- Positive Market Reaction: In pre-market trading on Nasdaq, Royalty Pharma shares rose 1.4% to $47.00, reflecting market optimism regarding the co-funding agreement and its potential financial benefits.
See More
Royalty Pharma Enters Agreement to Propel Development of JNJ-4804 for Autoimmune Disorders
Agreement Overview: Royalty Pharma has entered into an agreement to advance the development of JNJ-4804, a treatment for autoimmune diseases.
Focus on Autoimmune Diseases: The collaboration aims to enhance the research and development efforts for JNJ-4804, targeting various autoimmune conditions.
See More
Royalty Pharma Reveals $500 Million R&D Co-Funding Partnership with Johnson & Johnson for 2026-2027
Funding Announcement: Royalty Pharma has announced a $500 million R&D co-funding agreement with Johnson & Johnson for the years 2026-2027.
Collaboration Details: The agreement aims to support the development of innovative therapies and enhance research capabilities between the two companies.
See More
